C2N Makes PrecivityAD2 Alzheimer’s Blood Test Available to Clinicians

By LabMedica International staff writers
Posted on 17 Nov 2026

Diagnosing Alzheimer’s disease can be challenging, particularly in patients with mild cognitive impairment or early dementia. Assessing brain amyloid pathology can guide clinical decisions, but diagnostic pathways may be complex. A newly available blood test aims to simplify this assessment in symptomatic adults aged 40 and older.

C2N Diagnostics’ FDA-cleared PrecivityAD2 blood test is now available for ordering by health care professionals. The first FDA-cleared Alzheimer’s disease test for adults with cognitive symptoms as young as 40, it is designed to support clinical evaluation and guide next steps, including consideration of disease-modifying treatment options.


Image Credit: iStock

PrecivityAD2 uses high-resolution mass spectrometry to measure two blood biomarkers: the percentage of phosphorylated tau 217 (%p-tau217) and the amyloid-beta 42/40 (Aβ42/40) ratio. A proprietary algorithm combines these measurements into the Amyloid Probability Score 2 (APS2), which indicates the likelihood of brain amyloid pathology, a hallmark of Alzheimer’s disease.

The test was clinically validated across different age groups, sexes, and disease stages, demonstrating consistent performance across common comorbidities, including metabolic, cardiovascular, autoimmune, oncologic, mental health, and renal conditions. It is intended to help health care professionals experienced in evaluating cognitive impairment assess the likelihood of brain amyloid pathology in primary and specialized care settings.

C2N’s diagnostic technologies have been used in more than 200 Alzheimer’s disease and related research studies in the United States and internationally. More than 90,000 Precivity-related biomarker measurements have been reported in peer-reviewed publications, with additional research manuscripts currently under review.

“We’ve been waiting for this moment since the FDA initially informed us that its review had cleared the PrecivityAD2 test. The availability of the PrecivityAD2 test across the country through health care professionals means patients and families will have a clearer picture of brain amyloid plaque, a hallmark sign of Alzheimer’s disease. Overall, this will help streamline and simplify the complex diagnostic pathway that many patients face when dealing with serious memory concerns,” said Dr. Joel Braunstein, C2N Co-Founder, CEO and President.


Latest Industry News